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over recent years. However, the application of the currently approved photosensitizers (PSs)
is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance
from the body. To overcome these limitations, there is a need for the development of new
classes of PSs with ruthenium(II) polypyridine complexes currently gaining momentum.
However, these compounds generally lack significant absorption in the biological spectral
window, limiting their application to treat deep-seated or large tumors. To overcome this
drawback, ruthenium(II) polypyridine complexes designed in silico with (E,E′)-4,4′-bisstyryl-
2,2′-bipyridine ligands show impressive 1- and 2-Photon absorption up to a magnitude higher
than the ones published so far. While nontoxic in the dark, these compounds are phototoxic
in various 2D monolayer cells, 3D multicellular tumor spheroids and are able to eradicate a
multiresistant tumor inside a mouse model upon clinically relevant 1-Photon and 2-Photon
excitation.
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ue to the increasing impact of cancer on the life quality
and mortality of humans, increasing research efforts are
devoted toward the development of anticancer drugs and
strategies. Among the most commonly used techniques to fight
this disease (i.e., surgery, chemotherapy, and radiotherapy),
photodynamic therapy (PDT) is receiving increasing attention
during the last decades. In PDT, a photosensitizer (PS) is acti-
vated upon light irradiation to generate reactive oxygen species
(ROS)1,2. As the majority of currently approved PSs are based on
tetrapyrrolic structures (i.e., porphyrin, chlorin, and phthalocya-
nine), these compounds share similar drawbacks (e.g., poor
aqueous solubility, aggregation, photobleaching, slow clearance
from the body, and hepatotoxicity)3–5. To overcome these lim-
itations, there is a need for the development of new classes of PSs.
Among others, the use of transition metal complexes6–11 and
especially, Ru(II) polypyridine complexes are gaining momentum
due to their attractive photophysical and chemical properties (i.e.,
strong luminescence, high singlet oxygen production, high che-
mical, and photophysical stability)12–22, with the compound
TLD-1433 having just entered phase II clinical trials for the
treatment of non-muscle invasive bladder cancer23–25. Despite
these remarkable properties, the vast majority of Ru(II) poly-
pyridine complexes are excited using either blue or UV-A light.
As the light tissue penetration depth is rather poor at these
wavelengths, the application of these compounds to treat deep-
seated or large tumors is limited26–30. To circumvent this draw-
back, there is a need for the development of PSs with an
absorption towards the biological spectral window (600–900 nm),
which can be achieved by a red-shifted one-photon (1P)
absorption or the use of a two-photon (2P) absorption process for
2P PDT, a technique that is not employed yet in the clinic.
Worthy of note, the use of dihydrolipoic acid-coated gold
nanoclusters was recently reported as an efficient 2P PDT agent31.
However, the ability of Ru(II) polypyridine complexes to absorb
2P simultaneously, expressed as the 2P cross-section, remains
relatively weak (~40–250 Goeppert-Mayer (GM)), limiting their
applications in this field of research32–38.
To tackle these drawbacks, herein, we report the design of Ru
(II) polypyridine complexes with a red-shifted 1P and excep-
tionally strong 2P absorption using an in silico optimization. The
resulting compounds were synthesized, characterized, and
photophysically and biologically evaluated in-depth. Strikingly,
while being able to overcome the limitations of clinically applied
PS, the compounds are phototoxic in various 2D monolayer cells,
3D multicellular tumor spheroids (MCTS) and able to eradicate a
multiresistant tumor inside a mouse model upon clinically rele-
vant 1P and 2P excitation.
Results
Rational design. With the aim of enhancing the absorption
properties of Ru(2,2′-bipyridine)3 without deterioration of its 1P
absorption properties, the bipyridine ligand was functionalized
with rigid π conjugated substituents acting as electron-donating
groups. This is expected to induce a 1P absorption red-shift
toward the biological spectral window by intercalation of donor-
centered orbitals in the Ru centered frontier orbitals manifold
(allowing transitions of metal-to-ligand charge transfer (MLCT)
and ligand-to-metal charge transfer (LMCT) character at low
energy). As trans-stilbene are highly effective 2P dyes39,40, it
would be of high interest to extend the ligand scaffold with such
a moiety as well as to include terminal donor groups, namely
(E,E′)-4,4′-bisstyryl-2,2′-bipyridine (L-H), (E,E′)-4,4′-bis[p-(N,N-
dimethylamino)styryl]-2,2′-bipyridine (L-NMe2) and (E,E′)-4,4′-
bis[p-methoxystyryl]-2,2′-bipyridine (L-OMe). The predicted
UV–vis spectra for the resulting complexes of L-H and the L-
OMe series (Supplementary Fig. 1) show the presence of two
main bands in the 400–600 nm region, stemming from both
MLCT/LMCT type transitions but also from ligand-centered (LC)
charge-transfer excitations. Detailed analysis of the 1P and of the
lowest lying 2P computed data (Supplementary Tables 1–4)
indicated that the most intense lowest lying 2P absorption pro-
cesses are associated with LCCT transitions with an average CT
distance of 2.9–6.3 Å. Overall, the computed data suggests that Ru
(II) coordinated (E,E′)-4,4′-bisstyryl-2,2′-bipyridine complexes
with donor substituents, have a red-shifted 1P and a strong 2P
absorption.
Synthesis and characterization. Before the synthesis of the final
compounds (Fig. 1), the experimental procedures to obtain the
corresponding ligands were optimized41–44 to a one-step high-



















































Fig. 1 Chemical structures of complexes 1–7 investigated in this study. The complexes were isolated as hexafluorophosphate salts.
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Having the ligands in hand, the desired complexes 1–7 were
synthesized. All compounds were analyzed by 1H, 13C-NMR,
ESI-HRMS (Supplementary Figs. 3–25) and their purity con-
firmed by HPLC as well as elemental analysis. In addition, the
ligands L-H, L-NMe2, and L-OMe as well as 3 were characterized
using single-crystal X-ray crystallography (Supplementary
Tables 5–6, Supplementary Figs. 26–29).
Photophysical evaluation. The photophysical properties of the
complexes (Table 1, Supplementary Fig. 30) were then experi-
mentally investigated to evaluate their potential as PDT PSs. In
agreement with theoretical findings, the compounds generally
show a red-shift of the first 1P absorption (Fig. 2a) band max-
imum of about 50–70 nm for the symmetric Ru(II) complexes, in
comparison to Ru(2,2′-bipyridine)345 as well as an absorption tail
toward the near-infrared region. Strikingly and in agreement with
theoretical data, the reported compounds have an exceptionally
strong 2P absorption (Fig. 2b) with values up to ~6800 GM,
which is an order of magnitude higher than the ones reported
before for other Ru(II) polypyridine complexes32–38. Interest-
ingly, the L-NMe2 coordinated complexes were found with larger
σ2 values than the L-OMe and L-H coordinated compounds.
Overall, the compounds have a 1P absorption tail towards, and a
strong 2P absorption, in the biological spectral window, poten-
tially allowing for the treatment of deep-seated or large tumors.
The luminescence quantum yields of the L-OMe coordinated
complexes (3: 1.1%, 5: 1.4%, 7: 2.8%) were found to be
significantly higher than those of the L-H coordinated (1: 1.9%)
or L-NMe2 coordinated (2: >0.1%, 4: 0.4%, 6: 0.5%) compounds.
All complexes were found to have excited state lifetimes in the
nanosecond range (Supplementary Figs. 31–37) in degassed
(222–542 ns) and aerated saturated (36–96 ns) solutions. As the
lifetimes drastically decrease in the presence of air, it indicates
that the excited state can interact with a component in the air. For
identification of the type of ROS produced upon light exposure,
electron spin resonance (ESR) spectroscopy was employed using
the singlet oxygen (1O2) scavenger 2,2,6,6–tetramethylpiperidine
and the •OOH or •OH radical scavenger 5,5-dimethyl-1-pyrroline
N-oxide. While no signals for the formation of •OOH or •OH
radicals were detected, the formation of 1O2 in acetonitrile and
PBS was confirmed by observation of the characteristic 1O2-
induced triplet signal in the ESR spectrum (Supplementary
Figs. 38–44). The amount of generated 1O2 was quantitatively
determined by two methods: directly by measurement of the
phosphorescence of 1O2; indirectly by monitoring the change in
absorbance of a 1O2 scavenger. The singlet oxygen quantum
yields were found to be between 16–77% in acetonitrile and
1–11% in an aqueous solution (Table 1). The comparison
between the values indicates that the L-OMe coordinated
complexes (3, 5, 7) are able to produce 1O2 more efficiently than
1 and the L-NMe2 coordinated Ru(II) complexes (2, 4, 6).
Overall, complex 7 was found with the highest singlet oxygen
quantum yield (acetonitrile: 68–77%, aqueous solution: 10–11%).
Stability. The stability of the compounds was investigated by
incubation in human plasma at 37 °C for 48 h. The comparison of
the HPLC chromatograms (Supplementary Figs. 45–51) showed
no change before and after incubation in human plasma for all
compounds, indicative of the stability of the complexes under
biological conditions. Additionally, the stability upon irradiation
was investigated (Supplementary Figs. 52–60) as the majority of
current clinically employed PSs suffer from this drawback.
Importantly, no significant differences in the absorption spectra
for the L-OMe coordinated complexes (3, 5, 7) and 1 were
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contrary, small changes in the absorption spectra of the L-NMe2
coordinated complexes (2, 4, 6), especially of 2, were observed,
suggesting that the complexes are slightly photobleaching. Wor-
thy of note, under identical experimental conditions, the
absorption spectra of the known PS Protoporphyrin IX (PpIX)
was found to be drastically changed, indicating a significantly
stronger photobleaching. The study of the effect of the irradiation
on the molecular structure of 2 by NMR spectroscopy suggests
the decomposition of the compound (Supplementary Fig. 61).
Biological evaluation on 2D monolayer cells. All compounds
were found to be lipophilic with high distribution coefficients
between an organic octanol and an aqueous PBS phase (Supple-
mentary Table 7). The time-dependent cellular uptake of the
complexes was then investigated in human cervical carcinoma
(HeLa) cells by determining the amount of Ru inside the cells by
inductively coupled plasma mass spectrometry (ICP-MS) at each
time point. The results show that the asymptotic maximum
(Supplementary Figs. 62–68) of the uptake of the compounds was
reached within 8 h. As expected, the compounds with a higher
lipophilicity, with the exception of 2, were found to have the
highest uptake (Supplementary Fig. 69). The uptake mechanism
of the complexes was then investigated by blocking various
pathways by preincubation with a cationic transporter (tetra-
ethylammonium chloride), metabolic (2-deoxy-D-glucose and
oligomycin), and endocytotic inhibitors (ammonium chloride or
chloroquine) as well as at reduced temperature (4 °C). Since all
compounds were found with a similar profile (Supplementary
Figs. 70–76), it suggests that these are internalized by the same
mechanism, namely an energy-dependent endocytosis pathway.
The localization of the complexes in HeLa cells was then inves-
tigated by confocal laser scanning microscopy. The distribution
pattern of the luminescence of the compounds by 1P-(Supple-
mentary Fig. 77) or 2P-(Supplementary Fig. 78) excitation was
compared with the ones of commercial dyes for major cellular
organelles (i.e., nucleus, mitochondria, lysosomes, golgi appara-
tus, and endoplasmic reticulum). As no significant congruency
was detected, it suggests that the complexes do not majorly
localize in these organelles. In addition, the cellular localization
was also investigated by separately extracting the cellular orga-
nelles (i.e., cytoplasm, mitochondria, lysosome, and nucleus) and
determining the amount of Ru inside each organelle by ICP-MS.
The results (Supplementary Fig. 79) indicate that all complexes
majorly localize in the cytoplasm with a small amount of unse-
lective accumulation.
After an assessment of the uptake and the generation of 1O2
upon light exposure in a cuvette, the generation of ROS inside of
HeLa cells upon 1P-(488 nm, Supplementary Fig. 80) or 2P- (800
nm, Supplementary Fig. 81) excitation was confirmed using the
probe 2′, 7′ -dichlorofluorescein diacetate. To study their
efficiency as PDT PSs, their cytotoxicity in the dark as well as
upon irradiation at 480 nm (10 min, 5.2 mW cm−2, 3.1 J cm−2) or
540 nm (40 min, 4.0 mW cm−2, 9.5 J cm−2) toward noncancerous
retinal pigment epithelium (RPE-1), HeLa, mouse colon carci-
noma (CT-26), and human glioblastoma astrocytoma (U373)
cells was investigated. Importantly, all complexes were found to
be nontoxic in the dark (IC50,dark > 100 μM) in all cell lines
(Supplementary Tables 8–9). This is an important requirement
for a PDT agent. As desired, all compounds were found to be
phototoxic in the micromolar range (IC50,480 nm= 0.7 ±
0.4 – 53.6 ± 3.2 μM, IC50,540 nm= 0.9 ± 0.3 – 83.1 ± 6.7 μM) in
the different cell lines employed in this study. As the lead
compound of this study, complex 7 had an IC50 value in the
nanomolar range in CT-26 cells (IC50,dark > 100 μM, IC50,480 nm=
0.7 ± 0.4 μM, IC50,540 nm= 0.9 ± 0.3 μM) with a PI value > 143.
Under identical experimental conditions, the anticancer drug
cisplatin and the well-known PS PpIX display a magnitude lower
(photo-)toxicity. The cell death mechanism of the complexes was
then evaluated by measuring the cell viability upon preincubation
with autophagy (3-methyladenine), apoptosis (Z-VAD-FMK),
paraptosis (cycloheximide) and necrosis (necrostatin-1) inhibi-
tors (Supplementary Fig. 82). While apoptosis was found to be
the cell death mechanism for 1–5, 6–7 triggered cell death by a
combination of apoptosis and paraptosis pathways.
Biological evaluation on 3D multicellular tumor spheroids.
After evaluation of the biological effects of the compounds on 2D
monolayer cells, their ability to act on 3D MCTS was investigated.
MCTS simulate the conditions found in clinically treated tumors
including hypoxia and proliferation gradients to the center46.
Consequently, the penetration of the compounds inside of HeLa
MCTS with a diameter of 800 μm was investigated by 1P and 2P
z-stack confocal laser scanning microscopy. 4–7 completely
penetrated the MCTS within 12 h with a strong luminescence
signal at every section depth, whereas 1–3 were mostly found on
the outer sphere (Supplementary Figs. 83–89). Upon an increased
incubation time up to 60 h, the remaining compounds were also
able to penetrate the MCTS, with the exception of 2, which
was still found mostly on the outer sphere (Supplementary
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Fig. 2 Absorption spectra of the complexes 1–7. a 1P absorption spectrum in acetonitrile and b 2P absorption spectrum in dichloromethane.
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1–7 (20 μM) in HeLa MCTS was investigated and compared with
the well-known PS tetraphenylporphyrin (H2TPP) (20 μM) and
cisplatin (10 μM, 30 μM). The compounds were incubated for
3 days in the dark as this time was shown to be required for
complete MCTS penetration. The MCTS were then exposed to 1P
(500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2) or 2P irra-
diation (800 nm, 10 J cm−2, and section interval of 5 μm) on day
3. During the whole time period, the shape and volume of the
MCTS was constantly monitored. As expected, the MCTS treated
with 1–7 or H2TPP in the dark (Fig. 3a, representative image of
MCTS: Supplementary Fig. 95) were asymptotically growing in
the same manner than the control group, indicating that the
compounds do not show any inhibitory effect, whereas cisplatin
showed a weak effect on the tumor growth. On the contrary, the
volume of the MCTS treated with complexes 1–7 and exposed to
1P or 2P irradiation (Fig. 3b, c, representative image of MCTS:
Supplementary Figs. 96–97) significantly shrank, demonstrating
their strong tumor inhibition effect.
To further study the effect the complexes have on the tumor
survival, the treated MCTS were stained with a cellular living cell
kit using Calcein AM (Fig. 4). The fluorescence images confirmed
that the MCTS treated with 1–7 in the dark and with 1–3 upon a
1P irradiation (500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2)
or 2P irradiation (800 nm, 10 J cm−2, and section interval of 5
μm) are still intact. The low phototoxic effect of 1–3 is caused by
the poor MCTS penetration. Promisingly, the MCTS treated with
4–7 and exposed to 1P or 2P light were completely eradicated.
The photodynamic effect using a 1P (500 nm, 16.7 min,
10.0 mW cm−2, and 10 J cm−2) and 2P irradiation (800 nm,
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Fig. 3 Tumor growth inhibition assay in HeLa MCTS. Change of the volume in MCTS in correlation to the time of the treatment. The MCTS were treated
with compounds 1–7 (20 μM, 2% DMSO, v%), H2TPP (20 μM, 2% DMSO, v%), and cisplatin (10 μM and 30 μM). The MCTS were a strictly kept in the
dark, b exposed to 1P irradiation (500 nm, 16.7 min, 10.0 mWcm−2, and 10 J cm−2), c exposed to 2P irradiation (800 nm, 10 J cm−2 with a section interval
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Fig. 4 Representative image of the cell viability assay in HeLa MCTS. MCTS were treated with compounds 1–7 (20 μM, 2% DMSO, v%) in the
dark for 3 days. After this time, MCTS were kept in the dark, exposed to 1P irradiation (500 nm, 16.7 min, 10.0mW cm−2, and 10 J cm−2) or 2P
irradiation (800 nm, 10 J cm−2, and section interval of 5 μm). After 2 days, the cell viability was assessed by measurement of the fluorescence of calcein
(λex= 495 nm, λem= 515 nm), which is generated in living cells from Calcein AM. The scale bar represents a length of 200 µm.
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determination of the ATP concentration (Supplementary
Table 10). Importantly, no measurable cytotoxicity in the dark
could be observed in HeLa MCTS for all compounds and 1–3
upon light exposure in agreement with the previous investiga-
tions. 4–6 were found to be phototoxic in the micromolar range
(IC50,500 nm= 6.8 ± 0.2 – 78.3 ± 5.1 μM, IC50,800 nm= 1.4 ± 0.2 –
87.3 ± 6.8 μM). Strikingly, the lead compound of this study 7
was found to be nontoxic in the dark at even higher
concentrations (IC50,dark > 300 μM), while being highly photo-
toxic in the low micromolar range (IC50,500 nm > 6.8 ± 0.2 μM,
IC50,800 nm > 1.4 ± 0.2) with exceptionally high PI values (PI500 nm
> 44, PI800 nm > 250). Importantly, under identical experimental
conditions, treatment with H2TPP did not show a cytotoxic effect
(IC50, dark= IC50,500 nm= IC50,800 nm > 100 μM), indicating that 7
is able to act at low drug and light doses compared to a clinically
utilized tetrapyrrolic compound.
Biological evaluation inside a mouse model. Capitalizing on the
superior photophysical (i.e., highest 1O2 production) and biolo-
gical properties (i.e., highest phototoxicity in 2D monolayer cells
and 3D MCTS, high cell penetration), the properties of 7 to act as
a PDT PS were further investigated in a mouse model. To ensure
solubility and biocompatibility, the PS was converted to a chloride
salt using a counter ion exchange resin. We note at this stage that
a change of the counter ion can have a significant effect on the
biological properties of a metal complex. It was previously shown
that a counter ion can cause an undesired cytotoxicity or the
formation of nanoaggregates or a colloid due to poor water
solubility47. It was also reported that the cellular uptake of a Ru(II)
complex can dramatically change48. A challenging to treat mul-
tiresistant doxorubicin-selected P-gp-overexpressing human colon
cancer tumor model (SW620/AD300) was used to evaluate the PS
potential. The biodistribution of 7 (2 mg kg−1) inside this mouse
model was then time-dependently (30min, 1 h, 2 h) studied by
intravenous tail injection into nude mice. After each time point,
the mice were sacrificed and the major organs (i.e., blood, spleen,
intestine, stomach, liver, kidney, uterus, lung, heart, brain, and
tumor) were separated, ground and the Ru content determined by
ICP-MS. Interestingly, 7 was absorbed from the blood stream
within 1 h with a high accumulation in the intestine and some
accumulation in the tumor (Supplementary Fig. 98). Following
this, 1 h after an intravenous tail injection of 7 (2 mg kg−1), in vivo
PDT experiments using a 1P (500 nm, 60min, 10.0 mW cm−2,
and 36 J cm−2) or 2P irradiation (800 nm, 50mW, 1 kHz, pulse
width 35 fs, and 5 s mm−1) were performed on mice with an
80mm3 tumor. Encouragingly, after only one PDT treatment, the
tumor drastically shrank until they were nearly eradicated whereas
the tumors treated with the light or 7 in the dark (Fig. 5a, c) kept
growing. Importantly, the animals treated with the compound
behaved normally, without signs of pain, stress or discomfort and
did not lose or gain weight (Fig. 5b). After the treatment, the mice
were sacrificed, the tumor and organs were separated and histo-
logically examined by an H&E stain. The tumor tissue treated with
7 and exposed to light displayed pathological alterations caused by
the PDT treatment (Supplementary Fig. 99), while all other organs
did not show any significant effect (Supplementary Fig. 100).
Overall, this study demonstrates the enormous potential of 7 as a
PS for 1P and 2P PDT.
In summary, Ru(II) polypyridine complexes with (E,E′)-4,4′-
bisstyryl-2,2′-bipyridine ligands have been rationally designed
using DFT calculations and were found to have a remarkable red-
shifted 1P absorption as well as exceptionally high 2P cross
sections. The complexes were found to be taken up by cancerous
cells through an energy-dependent endocytosis pathway and to
accumulate in the cytoplasm. Upon irradiation, they were found
to generate 1O2, causing a phototoxic effect by apoptosis and
paraptosis pathways in various monolayer cells as well as MCTS.
In vivo studies confirmed the impressive ability of 7 to act as a PS
upon treatment at clinically relevant 1P (500 nm) and 2P (800
nm) irradiation with an eradication of the tumor. Importantly,
these compounds were found to be highly water soluble, stable in
human plasma, as well as upon constant irradiation and therefore
are able to overcome the limitations of currently employed PSs.
We strongly believe that these complexes have great potential for
preclinical trials.
Methods
Computational details. All calculations were performed at DFT (ground state)
and TD-DFT (excited state) level using the global hybrid B3LYP functional. The
Los Alamos (LANL2) effective core potential and the corresponding triple-zeta
basis set was applied to describe the Ruthenium atom, with all other atoms were
described by a Pople double-zeta basis set with a single set of polarization functions
on non-hydrogen atoms (6–31G(d)). All structures used correspond to ground
state minima on the ground state potential energy surfaces. Solvent effect (acet-
onitrile) were taken into account using the PCM model for structural optimizations
while single point calculations in the gas phase were performed to simulate 1P and
2P absorption spectra. All calculations were performed using the Gaussian suite of
programs except for the 2PA spectra which were simulated using the DALTON
software.
Materials. All chemicals were purchased from commercial sources and used
without further purification. If necessary, solvents were dried over molecular sieves.
The Ru(II) precursors Ru(DMSO)4Cl249 and Ru(2,2′-bipyridine)2Cl250 were syn-
thesized according to previously reported procedures. The pooled human plasma
was obtained from Biowest. The cell culture media and reagents were purchased
from Fisher Scientific.
Instrumentation and methods. 1H and 13C-NMR spectra were measured on a
Bruker 400MHz or 500MHz NMR spectrometer. Chemical shifts (δ) are reported
in parts per million (ppm) referenced to tetramethylsilane (δ 0.00) ppm using the
residual proton solvent peaks as internal standards and coupling constants (J) in
Hertz (Hz). The multiplicity of the peaks is abbreviated as follows: s (singlet), d
(doublet), dd (doublet of doublet), t (triplet), m (multiplet). ESI-MS experiments
were carried out using a LTQ-Orbitrap XL from Thermo Scientific and operated in
positive ionization mode with a spray voltage of 3.6 kV. No Sheath and auxiliary
gas was used. Applied voltages were 40 and 100 V for the ion transfer capillary and
the tube lens, respectively. The ion transfer capillary was held at 275 °C. Detection
was achieved in the Orbitrap with a resolution set to 100,000 (at m z−1 400) and
a m z−1 range between 150 and 2000 in profile mode. Spectrum was analyzed using
the acquisition software XCalibur 2.1 (Thermo Fisher Scientific). The automatic
gain control allowed accumulation of up to 2 × 105 ions for FTMS scans, maximum
injection time was set to 300 ms and 1 µscan was acquired. Ten microliters was
injected using a Thermo Finnigan Surveyor HPLC system (Thermo Fisher Scien-
tific) with a continuous infusion of methanol at 100 µL min−1. Elemental micro-
analyses were performed on a Thermo Flash 2000 elemental analyzer. For analytic
and preparative HPLC the following system has been used: 2 × Agilent G1361 1260
Prep Pump system with Agilent G7115A 1260 DAD WR Detector equipped with
an Agilent Pursuit XRs 5C18 (Analytic: 100 Å, C18 5 μm, 250 × 4.6 mm, Pre-
parative: 100 Å, C18 5 μm 250 × 300 mm) column and an Agilent G1364B 1260-FC
fraction collector. The solvents (HPLC grade) were millipore water (0.1% tri-
fluoroacetic acid, solvent A) and acetonitrile (0.1% trifluoroacetic acid, solvent B).
ICP-MS experiments were carried out on an iCAP RQ ICP-MS instrument
(Thermo Fisher).
Synthesis. (E,E′)-4,4′-Bisstyryl-2,2′-bipyridine: The synthesis of (E,E′)-4,4′-Bis-
styryl-2,2′-bipyridine is already published but in this study another synthetic route
was employed. 4,4′-Dimethyl-2,2′-bipyridine (1000 mg, 5.43 mmol, 1.0 equiv.) was
dissolved in dry N,N-dimethylformamide under nitrogen atmosphere and ben-
zaldehyde (1.2 mL, 11.84 mmol, 2.2 equiv.) was added to the solution. Afterwards
potassium tert-butoxide (2436 mg, 21.72 mmol, 4.0 equiv.) was added slowly. The
color of the solution turned to green and the mixture was stirred for 24 h. After that
the mixture was poured into water (400 mL) and the suspension cooled down to
5 °C. The crude product which precipitated, was filtered and washed with
methanol. The product was purified by recrystallization from boiling acetic acid.
The obtained solid was dissolved in dichloromethane and the mixture was washed
with a 5% aqueous lithium chloride solution, brine and water. The solvent was
removed and the product was isolated by recrystallization from boiling acetic acid.
1292 mg of (E,E′)-4,4′-Bisstyryl-2,2′-bipyridine (3.58 mmol, 66%) were yielded as a
beige solid. The experimental data obtained is in agreement with the previous
literature51.
(E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine: The synthesis of
(E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine is already published but
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16993-0
6 NATURE COMMUNICATIONS |         (2020) 11:3262 | https://doi.org/10.1038/s41467-020-16993-0 | www.nature.com/naturecommunications
in this study another synthetic route was employed. 4,4′-Dimethyl-2,2′-bipyridine
(1000mg, 5.43 mmol, 1.0 equiv.) was dissolved in dry N,N-dimethylformamide
(100mL) under nitrogen atmosphere and potassium tert-butoxide (2437mg, 21.72
mmol, 4.0 equiv.) was added slowly. After 1.5 h of stirring, 4-(dimethylamino)
benzaldehyde (1701 mg, 11.40mmol, 2.1 equiv.) was added to the reaction mixture.
The color of the solution turned to yellow and the mixture was heated at 90 °C for
19 h. After that the mixture was poured into water (400mL) and the suspension
cooled down to 5 °C. The crude product which precipitated, was filtered and washed
with water and diethyl ether. The product was isolated by recrystallization from
dichloromethane/pentane. 1541 mg of (E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-
2,2′-bipyridine (3.45mmol, 64%) were yielded as a yellow solid. The experimental
data obtained is in agreement with the previous literature52.
(E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine: The synthesis of (E,E′)-4,4′-Bis
[p-methoxystyryl]-2,2′-bipyridine is already published but in this study another
synthetic route was employed. 4,4′-Dimethyl-2,2′-bipyridine (532 mg, 2.89 mmol,
1.0 equiv.) was dissolved in dry N,N-dimethylformamide (25 mL) under nitrogen
atmosphere and 4-methoxybenzaldehyde (0.88 mL, 7.22 mmol, 2.5 equiv.) was
added to the solution. Afterwards potassium tert-butoxide (1360 mg, 12.13 mmol,
4.2 equiv.) was added slowly. The color of the solution turned to green and the
mixture was stirred for 24 h. After that the mixture which turned bright was poured
into water (200 mL) and the suspension cooled down to 5 °C. The crude product
which precipitated, was filtered, and washed with methanol. The product was
purified by recrystallization from boiling acetic acid. The obtained solid was
dissolved in dichloromethane and the mixture was washed with a 5% aqueous
lithium chloride solution, brine and water. The solvent was removed and the
product was isolated by recrystallization from boiling acetic acid. 925 mg of (E,E′)-
4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine (2.20 mmol, 76%) were yielded as a beige
solid. The experimental data obtained is in agreement with the previous
literature52.
[Ru(E,E′)-4,4′-Bisstyryl-2,2′-bipyridine)3][PF6]2 (1): (E,E′)-4,4′-Bisstyryl-2,2′-
bipyridine (400 mg, 1.11 mmol, 4.0 equiv.) and Ru(DMSO)4Cl2 (134 mg, 0.28
mmol, 1.0 equiv.) were suspended in dry ethanol (150 mL) under nitrogen
atmosphere and the mixture was refluxed for 24 h. Then the solution was cooled
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Fig. 5 Biological Evaluation of 7 inside a mouse model. In vivo PDT study of 7 using 1P (500 nm, 60min, 10.0 mWcm−2, and 36 J cm−2) or 2P (800 nm,
50mW, 1 kHz, pulse width 35 fs, and 5 s mm−1) excitation on nude mice bearing a doxorubicin-selected P-gp-overexpressing human colon cancer tumor
(SW620/AD300). a Tumor growth inhibition curves upon treatment. b Average body weights of the tumor-bearing mice. c Representative photographs of
the tumor-bearing mice. The error bars correspond to the standard deviation of the five replicates.
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saturated aqueous solution of ammonium hexafluorophosphate was added. The
crude product, which precipitated as a hexafluorophosphate salt was collected by
centrifugation and washed with ethanol, water and diethyl ether. The product was
dissolved in dichloromethane and washed with a 5% aqueous lithium chloride
solution, brine and water. After drying, 323 mg of 1 (0.22 mmol, 79%) were yielded
as a red solid. 1H-NMR (500MHz, CD3CN): δ 8.76 (d, J= 1.8 Hz, 6H), 7.78 (d, J=
16.4 Hz, 6H), 7.76 (d, J= 5.9 Hz, 6H), 7.71–7.69 (m, 12H), 7.51 (dd, J= 5.9, 1.8 Hz,
6H), 7.49–7.46 (m, 12H), 7.44–7.40 (m, 6H), 7.33 (d, J= 16.4 Hz, 6H); 13C-NMR
(125MHz, CD3CN): δ 158.2, 152.4, 147.6, 137.3, 136.8, 130.6, 130.1, 128.4, 125.4,
125.1, 121.7; HRMS (m/z): [M]2+ calcd. for C78H60N6Ru, 591.1956; found,
591.1978; analysis (calcd., found for C78H60F12N6P2Ru+ 4.H2O): C (60.66, 60.62),
H (4.44, 4.43), N (5.44, 5.76). [Ru(E,E′)-4,4′-Bisstyryl-2,2′-bipyridine)3][Cl]2: The
counter ion hexafluorophosphate was exchanged to chloride by elution with
methanol from the ion exchange resin Amberlite IRA-410. Analysis (calcd., found
for C78H60Cl2N6Ru): C (74.75, 74.36), H (4.83, 4.51), N (6.71, 6.37).
[Ru((E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine)3][PF6]2 (2):
(E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine (338 mg, 0.76 mmol,
4.0 equiv.), Ru(DMSO)4Cl2 (92 mg, 0.19 mmol, 1.0 equiv.) and lithium chloride
(401 mg, 9.46 mmol, 50.0 equiv.) were dissolved in dry N,N-dimethylformamide
(50 mL) under nitrogen atmosphere. The mixture was refluxed for 48 h. The
solution was then cooled down and a saturated aqueous solution of ammonium
hexafluorophosphate was added. The crude product, which precipitated as a
hexafluorophosphate salt was collected by centrifugation and washed with ethanol,
water and diethyl ether. The residue was dissolved in dichloromethane and washed
with a 5% aqueous lithium chloride solution, brine and water. The solvent was
removed under reduced pressure and the crude product recrystallized from
dichloromethane/pentane. The product was isolated via fractionated precipitation
from acetonitrile by adding dropwise diethyl ether. 86 mg of 2 (0.05 mmol, 26%)
were yielded as a black solid. 1H-NMR (500MHz, CD3CN): δ 8.62 (d, J= 1.9 Hz,
6H), 7.66 (d, J= 16.2 Hz, 6H), 7.65 (d, J= 6.1 Hz, 6H), 7.55–7.52 (m, 12H), 7.38
(dd, J= 6.1, 1.9 Hz, 6H), 7.03 (d, J= 16.2 Hz, 6H), 6.81–6.78 (m, 12H), 3.01 (s,
36H); 13C-NMR (125MHz, CD3CN): δ 159.4, 158.1, 152.6, 148.3, 137.7, 130.0,
124.5, 124.4, 120.6, 119.7, 113.2, 40.4; HRMS (m/z): [M]2+ calcd. for C90H90N12Ru,
720.3222; found, 720.3247; analysis (calcd., found for C90H90F12N12P2Ru): C
(62.46, 62.54), H (5.24, 5.17), N (9.71, 9.79). [Ru((E,E′)-4,4′-Bis[p-(N,N-
dimethylamino)styryl]-2,2′-bipyridine)3][Cl]2: The counter ion
hexafluorophosphate was exchanged to chloride by elution with methanol from the
ion exchange resin Amberlite IRA-410. Analysis (calcd., found for
C90H90Cl2N12Ru): C (71.51, 71.19), H (6.00, 5.93), N (11.12, 10.84).
[Ru((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)3][PF6]2 (3): (E,E′)-4,4′-Bis
[p-methoxystyryl]-2,2′-bipyridine (286 mg, 0.68 mmol, 4.0 equiv.) and Ru
(DMSO)4Cl2 (82 mg, 0.17 mmol, 1.0 equiv.) were suspended in dry ethanol (50
mL) under nitrogen atmosphere. The mixture was refluxed for 15 h. The solution
was then cooled down and undissolved solid was removed by filtration. A saturated
aqueous solution of ammonium hexafluorophosphate was added and the crude
product, which precipitated as a hexafluorophosphate salt was collected by
filtration. The solid was washed with water and diethyl ether. The residue was
purified via fractionated precipitation from acetonitrile by adding dropwise diethyl
ether. The collected product was dissolved in dichloromethane and washed with a
5% aqueous lithium chloride solution, brine and water. After drying, 218 mg of 3
(0.13 mmol, 76%) were yielded as a black solid. 1H-NMR (500MHz, CD3CN): δ
8.79 (d, J= 1.7 Hz, 6H), 7.79 (d, J= 16.4 Hz, 6H), 7.71 (d, J= 6.0 Hz, 6H), 7.64 (d,
J= 8.9 Hz, 12H), 7.44 (d, J= 6.0, 1.7 Hz, 6H), 7.17 (d, J= 16.4 Hz, 6H), 7.00 (d,
J= 8.9 Hz, 12H), 3.83 (s, 18H). 13C-NMR (125MHz, CD3CN): δ 162.0, 158.2,
152.2, 148.0, 137.0, 130.1, 129.5, 125.0, 122.7, 121.3, 115.5, 56.2; HRMS (m/z):
[M]2+ calcd. for C84H72N6O6Ru, 681.2290; found, 681.2273; analysis (calcd.,
found for C84H72F12N6O6P2Ru): C (61.05, 61.17), H (4.39, 4.44), N (5.09, 5.21).
[Ru((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)3][Cl]2: The counter ion
hexafluorophosphate was exchanged to chloride by elution with methanol from the
ion exchange resin Amberlite IRA-410. Analysis (calcd., found for
C84H72Cl2N6O6Ru): C (70.38, 70.62), H (5.06, 5.28), N (5.86, 5.57).
[Ru(2,2′-bipyridine)((E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-
bipyridine)2][PF6]2 (4): (E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-
bipyridine (220 mg, 0.49 mmol, 2.0 equiv.), Ru(DMSO)4Cl2 (119 mg, 0.25 mmol,
1.0 equiv.), and lithium chloride (1044 mg, 24.63 mmol, 100 equiv.) were
suspended in dry N,N-dimethylformamide (30 mL) under nitrogen atmosphere.
The mixture was refluxed for 4 h. The solution was then cooled down and water
was added. The crude product, which precipitated was collected by filtration and
washed with water and diethyl ether. The formation of [Ru((E,E′)-4,4′-Bis[p-(N,N-
dimethylamino)styryl]-2,2′-bipyridine)2Cl2] was analyzed via HPLC. [Ru((E,E′)-
4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine)2Cl2] and 2,2′-bipyridine
(47 mg, 0.3 mmol, 1.2 equiv.) were suspended in dry ethanol (50 mL) under
nitrogen atmosphere. The mixture was refluxed for 7 h. The solution was then
cooled down and undissolved solid was removed by filtration. A saturated aqueous
solution of ammonium hexafluorophosphate was added and the crude product,
which precipitated as a hexafluorophosphate salt was collected by filtration. The
solid was washed with water and diethyl ether. The residue was purified via
preparative HPLC as a trifluoroacetic acid salt. The solvents were millipore water
with 0.1% trifluoroacetic acid (solvent A) and acetonitrile (solvent B). The
following HPLC gradient has been used: 0–3 min: isocratic 50% A (50% B); 3–17
min: linear gradient from 50% A (50% B) to 0% A (100% B); 17–23 min: isocratic
0% A (100% B). The flow rate was 20 mLmin−1 and the chromatogram was
detected at 250, 350, and 450 nm. The collected product was dissolved in water and
a saturated aqueous solution of ammonium hexafluorophosphate was added. The
product, which precipitated as a hexafluorophosphate salt was collected by
filtration and washed with water, diethyl ether and pentane. 89 mg of 4 (0.06 mmol,
24%) were yielded as a dark red solid. 1H-NMR (400MHz, CD3CN): δ 8.61 (s, 4H),
8.50 (d, J= 8.2 Hz, 2H), 8.04 (td, J= 8.0, 1.5 Hz, 2H), 7.86 (ddd, J= 5.7, 1.4, 0.6 Hz,
2H), 7.66 (dd, J= 16.2, 1.9 Hz, 4H), 7.64 (d, J= 6.3 Hz, 2H), 7.56–7.50 (m, 10H),
7.43–7.34 (m, 6H), 7.02 (dd, J= 16.2 Hz, 4H), 6.81–6.77 (m, 8H), 3.02 (s, 12H),
3.01 (s, 12H); 13C-NMR (100MHz, CD3CN): δ 158.1, 158.0, 152.7, 152.6, 151.9,
151.9, 148.5, 138.3, 137.9, 130.0, 128.4, 125.1, 124.4, 120.7,119.6, 113.2, 40.4; HRMS
(m/z): [M]2+ calcd. for C70H68N10Ru, 575.2330; found, 575.2347; analysis (calcd.,
found for C70H68F12N10P2Ru): C (58.37, 58.19), H (4.76, 4.62), N (9.72, 9.72).
[Ru(2,2′-bipyridine)((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)2][PF6]2 (5):
(E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine (490 mg, 1.17 mmol, 2.0 equiv.),
Ru(DMSO)4Cl2 (282 mg, 0.58 mmol, 1.0 equiv.), and lithium chloride (2470 mg,
58.26 mmol, 100 equiv.) were suspended in dry N,N-dimethylformamide (75 mL)
under nitrogen atmosphere. The mixture was refluxed for 6 h. The solution was
then cooled down and purged into water. The crude product, which precipitated
was collected by filtration and washed with water and diethyl ether. The formation
of [Ru((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)2Cl2] was analyzed via
HPLC. [Ru((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)2Cl2] and 2,2′-
bipyridine (109 mg, 0.70 mmol, 1.2 equiv.) were suspended in dry ethanol (100 mL)
under nitrogen atmosphere. The mixture was refluxed for 6 h. The solution was
then cooled down and undissolved solid was removed by filtration. A saturated
aqueous solution of ammonium hexafluorophosphate was added and the crude
product, which precipitated as a hexafluorophosphate salt was collected by
centrifugation. The solid was washed with water and diethyl ether. The residue was
purified via preparative HPLC as a trifluoroacetic acid salt. The solvents were
millipore water with 0.1% trifluoroacetic acid (solvent A) and acetonitrile (solvent
B). The following HPLC gradient has been used: 0–3 min: isocratic 50% A (50% B);
3–17 min: linear gradient from 50% A (50% B) to 0% A (100% B); 17–23 min:
isocratic 0% A (100% B). The flow rate was 20 mLmin−1 and the chromatogram
was detected at 250, 350, and 450 nm. The collected product was dissolved in water
and a saturated aqueous solution of ammonium hexafluorophosphate was added.
The product, which precipitated as a hexafluorophosphate salt was collected by
filtration and washed with water, diethyl ether and hexane. 248 mg of 5 (0.18
mmol, 31%) were yielded as a dark red solid. 1H-NMR (400MHz, CD3CN): δ 8.72
(d, J= 1.6 Hz, 4H), 8.51 (d, J= 8.2 Hz, 2H), 8.06 (td, J= 8.0, 1.3 Hz, 2H), 7.85 (dd,
J= 5.6, 1.1 Hz, 2H), 7.75–7.68 (m, 6H), 7.67–7.61 (m, 8H), 7.60 (d, J= 5.9 Hz, 2H),
7.46–7.39 (m, 6H), 7.17 (dd, J= 16.4, 2.1 Hz, 4H), 7.05–6.99 (m, 8H), 3.85 (s, 6H),
3.84 (s, 6H); 13C-NMR (100MHz, CD3CN): δ 162.0, 158.1, 152.6, 152.2, 148.1,
138.6, 137.1, 132.8, 130.1, 129.5, 128.5, 125.2, 125.0, 122.7, 121.3, 115.5, 56.2;
HRMS (m/z): [M]2+ calcd. for C66H56N6O4Ru, 549.1698; found, 549.1707; analysis
(calcd., found for C66H56F12N6O4P2Ru+ C6H14): C (57.96, 58.33), H (4.44, 4.08),
N (5.87, 5.79).
[Ru(2,2′-bipyridine)2((E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-
bipyridine)][PF6]2 (6): Ru(2,2′-bipyridine)2Cl2 (350 mg, 0.72 mmol, 1.0 equiv.) and
(E,E′)-4,4′-Bis[p-(N,N-dimethylamino)styryl]-2,2′-bipyridine (388 mg, 0.87 mmol,
1.2 equiv.) were suspended in dry ethanol (50 mL) under nitrogen atmosphere and
the mixture was refluxed for 6 h. Then the solution was cooled down and a
saturated aqueous solution of ammonium hexafluorophosphate was added. The
crude product, which precipitated as a hexafluorophosphate salt was collected by
filtration and washed with water and diethyl ether. The product was isolated via
fractionated precipitation from acetonitrile by adding dropwise diethyl ether. 449
mg of 6 (0.39 mmol, 54%) were yielded as a dark red solid. 1H-NMR (500MHz,
CD3CN): δ 8.62 (d, J= 1.7 Hz, 2H), 8.50 (d, J= 8.2 Hz, 4H), 8.07–8.02 (m, 4H),
7.87–7.84 (m, 2H), 7.75–7.72 (m, 2H), 7.67 (d, J= 16.3 Hz, 2H), 7.57–7.52 (m, 4H),
7.52–7.49 (d, J= 6.0 Hz, 2H), 7.44–7.34 (m, 6H), 7.02 (d, J= 16.3 Hz, 2H),
6.81–6.76 (m, 4H), 3.01 (s, 12H); 13C-NMR (125MHz, CD3CN): δ 158.1, 158.0,
158.0, 152.7, 152.7, 152.6, 151.9, 148.8, 138.6, 138.0, 130.0, 128.5, 128.5, 125.2,
124.4, 124.3, 120.8, 119.5, 113.1, 40.4; HRMS (m/z): [M]2+ calcd. for C50H46N8Ru,
430.1439; found, 430.1441; analysis (calcd., found for C50H46F12N8P2Ru): C (52.22,
51.97), H (4.03, 4.04), N (9.74, 9.71).
[Ru(2,2′-bipyridine)2((E,E′)-4,4′-Bis[p-methoxystyryl]-2,2′-bipyridine)][PF6]2(7):
Ru(2,2′-bipyridine)2Cl2 (432 mg, 0.89 mmol, 1.0 equiv.) and (E,E′)-4,4′-Bis[p-
methoxystyryl]-2,2′-bipyridine (450 mg, 1.07 mmol, 1.2 equiv.) were suspended in
dry ethanol (100 mL) under nitrogen atmosphere and the mixture was refluxed for
6 h. Then the solution was cooled down and a saturated aqueous solution of
ammonium hexafluorophosphate was added. The crude product, which
precipitated as a hexafluorophosphate salt was collected by filtration and washed
with water and diethyl ether. The product was isolated via fractionated
precipitation from acetonitrile by adding dropwise diethyl ether. 358 mg of 7 (0.32
mmol, 36%) were yielded as a dark red solid. 1H-NMR (500MHz, CD3CN): δ 8.71
(d, J= 1.4 Hz, 2H), 8.51 (dd, J= 8.2, 0.7 Hz, 4H), 8.06 (td, J= 8.0, 1.5 Hz, 4H),
7.86–7.84 (m, 2H), 7.76–7.73 (m, 2H), 7.72 (d, J= 16.4 Hz, 2H), 7.66–7.62 (m, 4H),
7.59 (d, J= 6.0 Hz, 2H), 7.45–7.38 (m, 6H), 7.16 (d, J= 16.4 Hz, 2H), 7.03–6.98
(m, 4H), 3.83 (s, 6H). 13C-NMR (125MHz, CD3CN,): δ 162.0, 158.1, 158.0, 152.7,
152.6, 152.2, 148.2, 138.7, 138.7, 137.1, 130.1, 129.5, 128.6, 128.5, 125.2, 125.0,
122.6, 121.4, 115.5, 56.2; HRMS (m/z): [M]2+ calcd. for C48H40N6O2Ru, 417.1123;
found, 417.1126; analysis (calcd., found for C48H40F12N6O2P2Ru): C (51.30, 51.23),
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H (3.59, 3.48), N (7.48, 7.61). [Ru(2,2′-bipyridine)2((E,E′)-4,4′-Bis[p-(N,N-
methoxy)styryl]-2,2′-bipyridine)][Cl]2: The counter ion hexafluorophosphate was
exchanged to chloride by elution with methanol from the ion exchange resin
Amberlite IRA-410. Analysis (calcd., found for C48H40Cl2N6O2Ru): C (63.70,
63.51), H (4.46, 4.30), N (9.29, 9.11).
X-ray crystallography. Single-crystal X-ray diffraction data were collected at 160
(1) K for compounds L-H, L-NMe2, L-OMe, and 3 on a Rigaku OD XtaLAB
Synergy Dualflex (Pilatus 200K detector) diffractometer associated with an Oxford
liquid-nitrogen Cryostream cooler. The wavelength used for all experiments is
1.54184 Å and corresponds to the Cu Kα radiation (from a micro-focus sealed X-
ray tube). The single crystals were selected and cut (if needed) in polybutene oil,
mounted on a flexible loop, and transferred to the diffractometer on the goni-
ometer head. The program suite CrysAlisPro (version 1.171.39.13a) was used for
the pre-experiments, data collections, data reductions, and also for the analytical
absorption corrections53 based on the indexed faces. Using the Olex2 software54,
the crystal structures were solved with the SHELXT55 small molecule structure
solution program and refined with the SHELXL program package56 by full-matrix
least-squares minimization on F2. Molecular graphics were generated using Mer-
cury 4.057. The crystal data collections and structure refinement parameters are
summarized in Tables S1 and S2. CCDC 1951466 (for L-H), CCDC 1951467 (for
3), CCDC 1951468 (for L-NMe2), and CCDC 1951469 (for L-OMe) contain the
supplementary crystallographic data for these compounds, and can be obtained
free of charge from the Cambridge Crystallographic Data Center via www.ccdc.
cam.ac.uk/data_request/cif.
In the crystal structure of L-H, the substituted bipyridine is located on a center
of inversion, only one half of the molecule had to be refined, the second part being
reproduced by a symmetry operation. The main species cocystallized with solvent
molecules of acetic acid in a ratio 1:2, respectively.
In the crystal structure of L-OMe, there are two crystallographically
independent bipyridine molecules in the asymmetric unit: one complete molecule
and two half molecules on special positions for which the second half is reproduced
by a symmetry operation. Solvent molecules of acetic acid cocrystallized with the
main species in a ratio 2:1.
In the crystal structure of 3, the asymmetric unit contains two dicationic Ru
species, four anionic hexafluorophosphate counterions and one solvent molecule of
tetrahydropyran (disordered over three positions). The model was difficult to refine
because of the large number of non-hydrogen atoms in the asymmetric unit, and of
the disorders observed for the flexible terminal C=C(H)-C6H4OCH3 groups. The
crystal and the data collection were of a rather good quality but the final refinement
parameters remained relatively high (R1= 12% and wR2= 40%) or poor (Goof=
1.5). The solvent molecules could be identified in residual density peaks but
refinement was complicated and finally the real geometry of the tetrahydropyran
molecule was substituted by a regular planar six-membered ring. Many restraints
and constraints were used to get stable refinement cycles but the result seems to be
reliable, especially there is no ambiguity about the main charged species.
Spectroscopic measurements. The absorption spectra of the sample was mea-
sured with a SpectraMax M2 Spectrometer (Molecular Devices). For the mea-
surements of the emission, the sample was irradiated at 355 nm with a NT342B
Nd-YAG pumped optical parametric oscillator (Ekspla). The emission was focused
at right angle to the excitation pathway and directed to a Princeton Instruments
Acton SP-2300i monochromator. The signal was detected with a XPI-Max 4 CCD
camera (Princeton Instruments).
Two-photon absorption cross section. The two-photon absorption cross section
spectra of the sample was determined upon direction comparison to Rhodamine B.
The sample was irradiated with an OpoletteTM 355II (pulse width ≤ 100 fs, 80
MHz repetition rate, Spectra Physics Inc.) laser. The experimental excitation and
detection conditions were conducted with negligible reabsorption processes, which
could affect two-photon absorption measurements. The quadratic dependence of
the two-photon induced luminescence intensity on the excitation power was ver-
ified at an excitation wavelength of 800 nm. The two-photon absorption cross
section was calculated using the following equation:
σ2;sample ¼ σ2;reference ´ Φreference ´ creference ´ Isample ´ nsample
 
=
Φsample ´ csample ´ Ireference ´ nreference
  ; ð1Þ
σ2= two-photon cross section, Φ= luminescence quantum yield, c=
concentration, I= integrated luminescence intensity, n= refractive index
Luminescence quantum yield. The sample was prepared in an acetonitrile solu-
tion with an absorption of 0.1 at 355 nm. The sample was irradiated at 355 nm with
a NT342B Nd-YAG pumped optical parametric oscillator (Ekspla). The emission
was focused at right angle to the excitation pathway and directed to a Princeton
Instruments Acton SP-2300i monochromator. The signal was detected with a
XPI-Max 4 CCD camera (Princeton Instruments). The luminescence quantum
yields were determined by comparison with the reference [Ru(2,2′-bipyridine)3]Cl2
in acetonitrile (Φem= 5.9%)58 applying the following formula:








F ¼ 1  10A: ð3Þ
Φem= luminescence quantum yield, F= fraction of light absorbed, I= integrated
emission intensities, n= refractive index, A= absorbance of the sample at irra-
diation wavelength.
Lifetime. The sample was prepared in an air saturated as well as a degassed
acetonitrile solution with an absorption of 0.2 at 355 nm. The sample was irra-
diated at 355 nm with a NT342B Nd-YAG pumped optical parametric oscillator
(Ekspla). The emission was focused at right angle to the excitation pathway and
directed to a Princeton Instruments Acton SP-2300i monochromator. The signal
was detected with a R928 photomultiplier tube (Hamamatsu).
Electron spin resonance (ESR). The sample (10 μM) was dissolved in acetonitrile
or PBS containing 20 mM TEMP (2,2,6,6–tetramethylpiperidine) as a 1O2 sca-
venger or 20 mM DMPO (5,5-dimethyl-1-pyrroline N-oxide) as a •OOH or •OH
radical scavenger. Capillary tubes were filled with the solution and sintered by fire.
EPR spectra were recorded on a Bruker A300 spectrometer with 1 G field mod-
ulation, 100 G scan range, and 20 mW microwave power. The samples were
measured in exclusion from light and after irradiation (450 ± 10 nm, 60 s, and
21.8 mW cm−2).
Singlet oxygen. Direct evaluation: the sample was prepared in an air-saturated
acetonitrile or deuterated water solution with an absorption of 0.2 at 450 nm. The
sample was irradiated at 450 nm with a mounted M450LP1 LED (Thorlabs), whose
light was focused with aspheric condenser lenses. Using a T-Cube LED Driver
(Thorlabs), the intensity of the irradiation was varied and monitored with an
optical power and energy meter. The emission was focused at right angle to the
excitation pathway and directed to a Princeton Instruments Acton SP-2300i
monochromator. To cut off light at wavelengths shorter than 850 nm, a longpass
glass filter was placed in front of the monochromator entrance slit. The signal was
detected with an EO-817L IR-sensitive liquid-nitrogen cooled germanium diode
detector (North Coast Scientific Corp.). The luminescence signal, centered at
1270 nm, was measured from 1100 to 1400 nm. The obtained data were analyzed
upon plotting the integrated luminescence peaks against the percentage of the
irradiation intensity. The slope of the linear regression was calculated and com-
pared with the reference Rose Bengal (Φ= 76%)59. The absorption of the sample
was corrected with an absorption correction factor. The singlet oxygen quantum
yields were calculated using the following formula:









Φ= singlet oxygen quantum yield, S= slope of the linear regression of the plot
of the areas of the singlet oxygen luminescence peaks against the irradiation
intensity, I= absorption correction factor, I0= light intensity of the irradiation
source, and A= absorption of the sample at irradiation wavelength.
Indirect evaluation: measurement in acetonitrile: the sample was prepared in an
air-saturated acetonitrile solution with an absorption of 0.2 at the irradiation
wavelength, N,N-dimethyl-4-nitrosoaniline aniline (RNO, 24 µM) and imidazole
(12 mM). Measurement in PBS buffer: the sample was prepared in an air-saturated
PBS solution containing the complex with an absorption of 0.2 at the irradiation
wavelength, N,N-dimethyl-4-nitrosoaniline aniline (RNO, 20 µM) and histidine
(10 mM). The samples were irradiated for various time points with an Atlas
Photonics LUMOS BIO irradiator. The absorption of the samples was constantly
monitored with a SpectraMax M2 Microplate Reader (Molecular Devices). The
difference in absorption (A0−A) at 420 nm for the measurement in acetonitrile or
at 440 nm for the measurement in PBS was determined. The difference in
absorption was then plotted against the irradiation times and the slope of the linear
regression calculated. The absorption of the sample was corrected with an
absorption correction factor. The singlet oxygen quantum yields were calculated
using the same formulas as used for the direct evaluation.
Stability in human plasma. The stability of the sample was evaluated upon
incubation in pooled human plasma with caffeine as an internal standard, which
previously demonstrated to be stable under these conditions60. The sample (20 μM)
and caffeine (40 μM) were prepared in dimethyl sulfoxide stock solutions. One
aliquot of both solutions was added to 975 μL of human plasma achieving a total
volume of 1000 μL. The resulting solutions were incubated upon continuous gentle
shaking (ca. 300 rpm) for 48 h at 37 °C. After this time, the incubation was ended
by addition of 3 mL of methanol. The mixture was centrifuged for 60 min at
3000 rpm/958 gand 4 °C. The solution was filtered through a 0.2 μm membrane
filter. The solvent was evaporated and the residue was redissolved in 1:1 (v/v)
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acetonitrile/water with 0.1% trifluoroacetic acid. The resulting solution was then
filtered through a 0.2 μm membrane filter and analyzed with a HPLC System. The
solvents (HPLC grade) were millipore water with 0.1% trifluoroacetic acid (solvent
A) and acetonitrile (solvent B). Method M1: 0–3 min: isocratic 50% A (50% B);
3–17 min: linear gradient from 50% A (50% B) to 0% A (100% B); Method M2:
0–3 min: isocratic 95% A (5% B); 3–17 min: linear gradient from 95% A (5% B)
to 0% A (100% B); 17–23 min: isocratic 0% A (100% B). The flow rate was
1 mLmin−1 and the chromatogram was detected at 250 nm.
Photostability. The sample was prepared in an air-saturated acetonitrile solution.
Using a Atlas Photonics LUMOS BIO irradiator, the sample was constantly irra-
diated at 450 nm in time intervals from 0 to 10 min (13.2 J cm−2). The absorption
spectra from 350 to 700 nm was monitored with a SpectraMax M2 Microplate
Reader (Molecular Devices) at each time interval. As positive and negative controls,
respectively, [Ru(2,2′-bipyridine)3]Cl2 and Protoporphyrin IX were used.
Photobleaching. The sample was dissolved in air saturated 0.7 mL CD3CN and
stored in a NMR tube in the dark. A 1H-NMR spectrum was measured directly
after preparation to ensure the identity of the sample. The sample was then
irradiated at 450 nm with an Atlas Photonics LUMOS BIO irradiator (10 min,
13.2 J cm−2). Following this treatment, a 1H-NMR spectrum was again measured.
Distribution coefficient. Using the “shake-flask” method, the distribution coeffi-
cient between the PBS and octanol phase of the sample was determined. The PBS
and octanol phases were previously saturated in each other. The sample was dis-
solved in the phase, which is dissolving best the compound. This solution was
added to an equal volume of the other phase and mixed at 190 rpm overnight with
a sample mixer. Following this, the solutions were equilibrated for 4 h. The phases
were carefully separated from each other. The amount of the sample in each phase
was determined by ICP-MS. The evaluation was repeated three times and the ratio
between the organic and aqueous phase determined.
Cell culture. Human glioblastoma astrocytoma (U373) cells were cultured in MEM
medium supplemented with 10% FBS, 1% NEAA (nonessential amino acids), and
1% penicillin/streptomycin. Human cervical carcinoma (HeLa), doxorubicin-
resistant human colon adenocarcinoma (SW620/AD300), and the mouse colon
carcinoma (CT-26) cells were cultured in DMEM medium supplemented with 10%
FBS and 1% penicillin/streptomycin. Human retinal epithelial (RPE-1) cells were
cultured in DMEM-F12 medium supplemented with 10% FBS and 1% penicillin/
streptomycin. All cell lines were obtained from the American Type Culture Col-
lection and cultured at 37 °C and 5% CO2. Before an experiment, the cells were
passaged three times.
Time-dependent cellular uptake. A total of 6 × 106 cells were incubated with
the sample (10 μM, 2% DMSO, v%) for varying time points (0.5, 1, 2, 4, 8, 12 h) at
37 °C. After this time, the media was removed and the cells washed with cell media.
The cells were trypsinised, harvested, centrifuged, and resuspended. The number of
cells on the dish was counted. The sample was digested using a 60% HNO3 solution
for 3 days and, following this, diluted to a 2% HNO3 solution in water. The Ru
content was determined with an ICP-MS apparatus and the results compared with
the Ru references. The Ru content was then associated with the number of cells.
Cellular uptake mechanism. The cellular uptake mechanism was investigated
upon pretreatment of 1 × 106 cells with pathways inhibitors and determination of
the amount of Ru inside the cells with an ICP-MS apparatus.
Control: the cells were incubated with the sample (10 μM, 2% DMSO, v%) for
1 h at 37 °C and then washed with PBS. The cells were detached with trypsin,
harvested, centrifuged, and resuspended. The number of cells on the dish was
counted. The sample was digested using a 60% HNO3 solution for 3 days and
following this diluted to a 2% HNO3 solution in water. The Ru content was
determined with an ICP-MS apparatus and the results compared with the Ru
references. The Ru content was then associated with the number of cells.
Low temperature: the cells were preincubated at 4 °C for 1 h. After this time, the
cells were incubated with the sample (10 μM, 2% DMSO, v%) for 1 h at 37 °C and
then washed with PBS. The cells were detached with trypsin, harvested,
centrifuged, and resuspended. The number of cells on the dish was counted. The
sample was digested using a 60% HNO3 solution for 3 days and following this
diluted to a 2% HNO3 solution in water. The Ru content was determined with an
ICP-MS apparatus and the results compared with the Ru references. The Ru
content was then associated with the number of cells.
Metabolic inhibition: the cells were preincubated with 2-deoxy-D-glucose (50
mM) and oligomycin (5 μM) for 1 h. After this time, the cells were incubated with
the sample (10 μM, 2% DMSO, v%) for 1 h at 37 °C and then washed with PBS. The
cells were detached with trypsin, harvested, centrifuged, and resuspended. The
number of cells on the dish was counted. The sample was digested using a 60%
HNO3 solution for 3 days and following this diluted to a 2% HNO3 solution in
water. The Ru content was determined with an ICP-MS apparatus and the results
compared with the Ru references. The Ru content was then associated with the
number of cells.
Endocytic inhibition: the cells were preincubated with ammonium chloride
(50 mM) or chloroquine (100 μM) for 1 h. After this time, the cells were incubated
with the sample (10 μM, 2% DMSO, v%) for 1 h at 37 °C and then washed with
PBS. The cells were detached with trypsin, harvested, centrifuged, and resuspended.
The number of cells on the dish was counted. The sample was digested using a 60%
HNO3 solution for 3 days and following this diluted to a 2% HNO3 solution in
water. The Ru content was determined with an ICP-MS apparatus and the results
compared with the Ru references. The Ru content was then associated with the
number of cells.
Cation transporter inhibition: the cells were preincubated with
tetraethylammonium chloride (1 mM) for 1 h. After this time, the cells were
incubated with the sample (10 μM, 2% DMSO, v%) for 1 h at 37 °C and then
washed with PBS. The cells were detached with trypsin, harvested, centrifuged, and
resuspended. The number of cells on the dish was counted. The sample was
digested using a 60% HNO3 solution for 3 days and following this diluted to a 2%
HNO3 solution in water. The Ru content was determined with an ICP-MS
apparatus and the results compared with the Ru references. The Ru content was
then associated with the number of cells.
Intracellular distribution by confocal luminescence imaging. A total of 1 × 104
cells were seeded on confocal dishes and allowed to adhere overnight. The cells
were incubated with the sample (10 μM, 2% DMSO, v%) for 8 h at 37 °C in the
dark. After this time, the cells were washed with PBS. The cells were further each
incubated with LysoTracker Green, MitoTracker Deep Red, Cell-light Golgi-GFP,
ER tracker Green and Hoechst 33342 for 30 min at 37 °C in the dark. The cells were
washed three times with PBS. Confocal images were taken with a LSM 880 (Carl
Zeiss) laser scanning confocal microscope. The organelle trackers were excited and
detected as recommended by the supplier. The samples were detected under usage
of their 1-Photon (λex= 458 nm, λem= 600–750 nm) or 2-Photon (λex= 800 nm,
λem= 600–750 nm) luminescence properties.
Intracellular distribution by ICP-MS. A total of 10 × 106 cells were incubated with
the sample (10 μM, 2% DMSO, v%) for 8 h at 37 °C in the dark. After this time, the
cells were detached with trypsin and harvested. The number of cells was counted
and equally divided into four portions. In the first portion, the nucleus was
extracted using a nucleus extraction kit (Sangon Biotech); in the second portion,
the mitochondria was extracted using a mitochondria extraction kit (Sangon
Biotech), and in the third portion, the lysosome was extracted using a lysosome
extraction kit (GenMed Scientific). Using the fourth portion, the cytoplasm was
extracted. The cells were detached with trypsin, harvested, and centrifuged. The cell
pellet was resuspended in lysis buffer and the cells lysed. The cytoplasm was
separated by centrifugation(Optima MAX-XP ultracentrifuge, Beckman Coulter)
for 150 min at 200,000 g at 4 °C. The supernatant solution was separated. The
sample was digested using a 60% HNO3 solution for 3 days and following this
diluted to a 2% HNO3 solution in water. The Ru content was determined with an
ICP-MS apparatus and the results compared with the Ru references. The Ru
content was then associated with the number of cells.
One-photon induced cellular singlet oxygen generation. A total of 1 × 104 cells
were seeded on confocal dishes and allowed to adhere overnight. The cells were
incubated with the sample (10 μM, 2% DMSO, v%) for 4 h at 37 °C in the dark.
After this time, the cells were washed with PBS. The cells were further incubated
with 2′,7′-dichlorofluorescein diacetate for 30 min. The cells were washed three
times with PBS. The sample was irradiated upon 1-Photon excitation (λex=
488 nm). Confocal images (λex= 488 nm, λem= 510–550 nm) were taken with a
LSM 880 (Carl Zeiss) laser scanning confocal microscope.
Two-photon induced cellular singlet oxygen generation. A total of 1 × 104 cells
were seeded on confocal dishes and allowed to adhere overnight. The cells were
incubated with the sample (10 μM, 2% DMSO, v%) for 4 h at 37 °C in the dark.
After this time, the cells were washed with PBS. The cells were further incubated
with 2′,7′-dichlorofluorescein diacetate for 30 min. The cells were washed three
times with PBS. The sample was irradiated upon 2-Photon excitation (λex= 800
nm). Confocal images (λex= 488 nm, λem= 510–550 nm) were taken with a LSM
880 (Carl Zeiss) laser scanning confocal microscope.
(Photo-)cytotoxicity on 2D cell monolayers. A total of 4 × 103 cells were seeded
on 96-well plates and allowed to adhere overnight. The cells were treated with
increasing concentrations of the sample diluted in cell media achieving a total
volume of 200 μL. The cells were incubated with the sample for 8 h and, after this
time, the medium refreshed. To study the phototoxic effect of the sample, the cells
were exposed to 480 nm (spectral half-width: 20 nm, 10 min, 5.2 mW cm−2, 3.1 J
cm−2) or 540 nm (spectral half-width: 30 nm, 40 min, 4.0 mW cm−2, 9.5 J cm−2)
light using an Atlas Photonics LUMOS BIO irradiator. To study the dark cyto-
toxicity of the sample, the cells were not irradiated and the medium exchanged.
The cells were grown for an additional 40 h at 37 °C. After this time, the medium
was replaced with fresh medium containing resazurin with a final concentration of
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0.2 mgmL−1. The cells were incubated for 4 h and the amount of the fluorescent
product resorufin determined (λex= 540 nm, λem= 590 nm) with a SpectraMax
M2 Microplate Reader (Molecular Devices). The obtained data was analyzed with
the GraphPad Prism software.
Cell death mechanism. The cell death mechanism was investigated by measuring
the cell viability upon preincubation with various cell death pathway inhibitors. 3-
Methyladenine (100 μM), Z-VAD-FMK (20 μM), cycloheximide (0.1 μM), and
necrostatin-1 (60 μM) were preincubated with the cells for 40 min. Following this,
the sample (5 μM) was added and incubated for 8 h. The cells were washed, irra-
diated with a LED (500 nm, 10 min, 10.0 mW cm−2, 6 J cm−2) light source, and
incubated for 12 h. After this time, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide was added and the cells were incubated for additional 4 h. The
liquid was disposed and 150 μL DMSO was added. The plates were shaken for
2 min and the absorbance at 595 nm was measured using a microplate reader
(TecanInfiniteF200, Bio-rad).
Generation and analysis of 3D multicellular tumor spheroids (MCTS). A
suspension of 0.75% agarose in PBS was heated inside a high-pressure autoclave.
The hot emulsion was transferred into a 96-well plate (50 μL per well). The plates
were exposed for 3 h to UV irradiation and allowed to cool down. After this time, a
cell suspension of 3 × 103 cells was seeded on top the agarose ground layer. Within
2–3 days, MCTS were formed from the cell suspension. The MCTS were cultivated
and maintained at 37 °C in a cell culture incubator at 37 °C with 5% CO2 atmo-
sphere. The culture medium was replaced every 2 days. The formation, integrity,
diameter, and volume of the MCTS was monitored by an Axio Observer Z1 (Carl
Zeiss) phase contrast microscope. The volume was calculated using the following
equation: V= 4/3πr3. The luminescence images along the z-axis were captured by
1-Photon (λex= 458 nm, λem= 600–750 nm) or 2-Photon (λex= 800 nm, λem=
600–750 nm) excitation in the z-stack mode with a an LSM 880 (Carl Zeiss) laser
scanning confocal microscope equipped with Argon or Coherent Chameleon
2-Photon laser and a GaAsP detector.
3D multicellular tumor spheroids (MCTS) growth inhibition assay. MCTS were
treated with the sample (20 μM 1–7, 20 μM tetraphenylporphyrin H2TPP, 10 μM
cisplatin, 30 μM cisplatin, 2% DMSO, v%) by replacing 50% of the media with drug
supplemented media in the dark for 3 days. After this time, the MCTS were
exposed to a 1-Photon (500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2) irra-
diation using a LED light source or 2-Photon (800 nm, 10 J cm−2 with a section
interval of 5 μm) irradiation using a LSM 880 (Carl Zeiss) laser scanning confocal
microscope equipped with a Coherent Chameleon 2-Photon laser. The cell culture
media was replaced every 2 days. The integrity and diameter of the MCTs was
monitored with an Axio Observer Z1 (Carl Zeiss) phase contrast microscope
every 24 h.
3D multicellular tumor spheroids (MCTS) viability assay. MCTS were treated
with the sample (20 μM, 2% DMSO, v%) by replacing 50% of the media with drug
supplemented media in the dark for 3 days. After this time, the MCTS were
exposed to a 1-Photon (500 nm, 16.7 min, 10.0 mW cm−2, and 10 J cm−2) irra-
diation using a LED light source or 2-Photon (800 nm, 10 J cm−2 with a section
interval of 5 μm) irradiation using a LSM 880 (Carl Zeiss) laser scanning confocal
microscope equipped with a Coherent Chameleon 2-Photon laser. The cell culture
media was replaced every 2 days. Two days after the irradiation the MCTS viability
was tested using a Viability/Cytotoxicity Kit for mammalian cells (Invitrogen).
Living cells can be identified from dead cells through the presence of ubiquitous
intracellular esterase activity which can be monitored by the enzymatic conversion
of the non-fluorescent calcein AM to the intensely fluorescent calcein (λex=
495 nm, λem= 515 nm). As the spectroscopic properties of the dead cell probe
EthD-1 overlaps with the one of the investigated compounds, this probe was not
used and only calcein AM as a probe for living cells was used. The MCTS were
incubated with calcein AM (2 μM) for 30 min and images of the MCTS taken with
an Axio Observer Z1 (Carl Zeiss, Germany) inverted fluorescence microscope.
(Photo-)cytotoxicity on 3D multicellular tumor spheroids (MCTS). The cyto-
toxicity of the compounds in 3D MCTS was assessed by measurement of the ATP
concentration. MCTS were treated with increasing concentrations of the com-
pound (2% DMSO, v%) by replacing 50% of the media with drug supplemented
media and incubation for 12 h. After this time, the MCTS were divided in three
identical groups. The first group was strictly kept in the dark. The second group
was exposed to a 1-Photon irradiation (500 nm, 16.7 min, 10.0 mW cm−2, and
10 J cm−2) using a LED light source and the third group was exposed to a 2-Photon
irradiation (800 nm, 10 J cm−2 with a section interval of 5 μm) using a LSM 880
(Carl Zeiss, Germany) laser scanning confocal microscope equipped with a
Coherent Chameleon 2-Photon laser. After the irradiation, all groups were incu-
bated additional 48 h. The ATP concertation was measured using a CellTiter-Glo
3D Cell Viability kit (Promega) by measuring the generated chemiluminescence
with an infinite M200 PRO (Tecan) plate reader. The obtained data was analyzed
with the GraphPad Prism software.
In vivo experiment. Six weeks old nu/nu female mice were purchased from
Charles River. For the tumor xenograft, 6 × 106 SW620/AD300 cells were sub-
cutaneously (s.c.) injected with a 150 μL Matrigel and saline (1:1, v/v) suspension
into the mice. After a week, the tumor volumes of the mice reached ~80 mm3. All
experiments were conducted in compliance with the ethical regulations for animal
testing and received approval of the experimental animal managing committee of
Sun Yat Sen University.
In vivo biodistribution. Three nude mice were tail-intravenous (i.v.) injected with
2 mg kg−1 of the sample. One hour later, the mice were sacrificed and the major
organs (including the heart, liver, spleen, lung, kidney, brain, intestine, and blood)
were separated, weighted and ground. The grinded organ as well as the blood were
digested using a 60% HNO3 solution for 3 days, and following this, diluted to a 2%
HNO3 solution in water. The Ru content was determined with an ICP-MS appa-
ratus and the results compared with the Ru references.
In vivo time-dependent biodistribution. Six SW620/AD300 nude tumor-bearing
nude mice were separated into three groups, and i.v. injected with 2 mg kg−1 of the
sample. 30 min, 1 h, 2 h later, the mice were euthanized and the distribution of the
sample determined using the previous described method.
In vivo (Photo-)cytotoxicity. 30 SW620/AD300 nude tumor-bearing nude mice
were randomly separated into six groups, resulting in five mice for each group.
After been anaesthetized, the mice was fixed in a warm three-axes holder. Before
irradiation, the tumor site was disinfected with ethanol. The tumor was exposed to
1P or 2P light. Following the irradiation, the operative area was disinfection by
iodophor.
Group 1: injected 7 (2 mg kg−1, 50 μL) intravenously and irradiate under
800 nm laser (50 mW, 1 kHz, pulse width 35 fs, 5 s mm−1) 1 h after injection;
Group 2: injected 7 (2 mg kg−1, 50 μL) intravenously and irradiate under
500 nm light (60 min, 10.0 mW cm−2, 36 J cm−2) 1 h after injection;
Group 3: injected by physiological saline (50 μL) and treated with 800 nm laser
(50 mW, 1 kHz, pulse width 35 fs, 5 s mm−1) 1 h after injection;
Group 4: injected by physiological saline (50 μL) and treated with 500 nm light
(60 min, 10.0 mW cm−2, 36 J cm−2) 1 h after injection;
Group 5: intravenous injected 7 (2 mg kg−1, 50 μL);
Group 6: injected 50 μL physiological saline.
The mice were anesthetized by injection of a 4% chloral hydrate aqueous
solution (0.2 mL, 20 g−1) before the treatment. The tumor volume and body weight
were measured and recorded every 2 days. Tumor volume was calculated by the
following formula:
Volume ¼ Length ´ Width2
 
=2: ð6Þ
Histological examination. The tumor and all major organs (including the heart,
liver, spleen, lung, kidney, brain, intestine, and blood) were collected and a slice of
each one was fixated with 4% paraformaldehyde. The obtained slices were stained
with hematoxylin and eosin. The histological images were taken with a Carl Zeiss
Axio Imager Z2 microscope.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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